Prognostic Value of the Physical Examination in Patients with Heart Failure and Atrial Fibrillation: Insights from the AF-CHF Trial
Guillem Caldentey(Hospital Clínic de Barcelona), Anique Ducharme(Montreal Heart Institute), Normand Racine(Montreal Heart Institute), Michel White(Montreal Heart Institute), Paul Khairy(Montreal Heart Institute), Hugues Leduc(Montreal Heart Institute), Denis Roy(Montreal Heart Institute), Mario Talajic(Montreal Heart Institute), Jean L. Rouleau(Montreal Heart Institute), Eileen O’Meara(Montreal Heart Institute)
Cited by 1
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure
|New England Journal of Medicine|2010|1.8k
Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure
|New England Journal of Medicine|2008|1.6k
Amiodarone to Prevent Recurrence of Atrial Fibrillation
|New England Journal of Medicine|2000|1.2k